Financial Information | Regeneron Pharmaceuticals Inc.

Filing date	Form	Description	View
May 03, 2024	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-24-000017.pdf 0001883850-24-000017.xls
May 02, 2024	8-K	Report of unscheduled material events or corporate event	View HTML 0001804220-24-000015.pdf 0001804220-24-000015.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 02, 2024	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001804220-24-000017.pdf 0001804220-24-000017.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 01, 2024	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-24-000012.pdf 0001883850-24-000012.xls
May 01, 2024	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-24-000013.pdf 0001883850-24-000013.xls
May 01, 2024	144	Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing	View HTML 0001950047-24-003300.pdf 0001950047-24-003300.xls
May 01, 2024	144	Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing	View HTML 0001968582-24-000345.pdf 0001968582-24-000345.xls
Apr 25, 2024	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001308179-24-000578.pdf 0001308179-24-000578.xls
Apr 25, 2024	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	View HTML 0001308179-24-000577.pdf 0001308179-24-000577.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Apr 25, 2024	ARS	An annual report to security holders	View HTML 0001104659-24-051965.pdf

Data provided by Kaleidoscope.

Investors & Media